Ivan Fan-Ngai Hung1,2, Desmond Yat-Hin Yap3, Terence Pok-Siu Yip4, Ricky Ruiqi Zhang1,2, Kelvin Kai-Wang To2, Kwok-Hung Chan2, Sydney Chi-Wai Tang3, Sing-Leung Lui4, Yotam Levin5, Efrat Kochba5, Johnson Yiu-Nam Lau2, Man-Fung Yuen1, Tak-Mao Chan3, Kwok-Yung Yuen2. 1. Division of Infectious Diseases, Department of Medicine, University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong Special Administrative Region, China. 2. Carol Yu's Centre for Infection and Division of Infectious Diseases, University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong Special Administrative Region, China. 3. Division of Nephrology, Department of Medicine, University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong Special Administrative Region, China. 4. Division of Nephrology, Department of Medicine, Tung Wah Hospital, Hong Kong Special Administrative Region, China. 5. NanoPass Technologies, Nes Ziona, Israel.
Abstract
BACKGROUND:Patients on dialysis are hyporesponsive to the hepatitis B virus vaccines (HBVv). We examined intradermal (ID) HBVv Sci-B-Vac, with topical Toll-like receptor 7 (TLR7) agonist imiquimod pretreatment in dialysis patients. METHODS: We enrolled and prospectively followed adult patients on dialysis between January 2016 and September 2018. Eligible patients were randomly allocated (1:1:1) into 1 treatment group, topical imiquimod cream followed by ID HBVv (IMQ + ID); and 2 control groups: topical aqueous cream (placebo) followed by ID HBVv (AQ + ID) or topical aqueous cream followed by intramuscular HBVv (AQ + IM). The primary endpoint was the seroprotection rate (hepatitis B surface antibody ≥10 mIU/mL) at 52 weeks. RESULTS:Ninety-four patients were enrolled, among which 57.4% were previous nonresponders. Seroprotection rate was significantly better at week 52 for the IMQ + ID group with 96.9% compared to 74.2% and 48.4% for AQ + ID and AQ + IM groups, respectively (P < .0001). The geometric mean concentration was significantly higher at week 52 for the IMQ + ID group: 1135 (95% confidence interval [CI], 579.4-2218.2) mIU/mL, compared to 86.9 (95% CI, 18.5-409.3) mIU/mL and 7.2 (2.0-26.5) mIU/mL for the AQ + ID and AQ + IM groups, respectively (P < .0001). IMQ + ID vaccination (odds ratio, 3.70 [95% CI, 1.16-11.81]; P = .027) was the only factor independently associated with higher 52-week seroprotection rate. Adverse reaction was infrequent. CONCLUSIONS: Pretreatment with topical imiquimod before ID HBVv Sci-B-Vac was safe with favorable seroprotection in dialysis patients. CLINICAL TRIALS REGISTRATION: NCT02621112.
RCT Entities:
BACKGROUND:Patients on dialysis are hyporesponsive to the hepatitis B virus vaccines (HBVv). We examined intradermal (ID) HBVv Sci-B-Vac, with topical Toll-like receptor 7 (TLR7) agonist imiquimod pretreatment in dialysis patients. METHODS: We enrolled and prospectively followed adult patients on dialysis between January 2016 and September 2018. Eligible patients were randomly allocated (1:1:1) into 1 treatment group, topical imiquimod cream followed by ID HBVv (IMQ + ID); and 2 control groups: topical aqueous cream (placebo) followed by ID HBVv (AQ + ID) or topical aqueous cream followed by intramuscular HBVv (AQ + IM). The primary endpoint was the seroprotection rate (hepatitis B surface antibody ≥10 mIU/mL) at 52 weeks. RESULTS: Ninety-four patients were enrolled, among which 57.4% were previous nonresponders. Seroprotection rate was significantly better at week 52 for the IMQ + ID group with 96.9% compared to 74.2% and 48.4% for AQ + ID and AQ + IM groups, respectively (P < .0001). The geometric mean concentration was significantly higher at week 52 for the IMQ + ID group: 1135 (95% confidence interval [CI], 579.4-2218.2) mIU/mL, compared to 86.9 (95% CI, 18.5-409.3) mIU/mL and 7.2 (2.0-26.5) mIU/mL for the AQ + ID and AQ + IM groups, respectively (P < .0001). IMQ + ID vaccination (odds ratio, 3.70 [95% CI, 1.16-11.81]; P = .027) was the only factor independently associated with higher 52-week seroprotection rate. Adverse reaction was infrequent. CONCLUSIONS: Pretreatment with topical imiquimod before ID HBVv Sci-B-Vac was safe with favorable seroprotection in dialysis patients. CLINICAL TRIALS REGISTRATION: NCT02621112.
Authors: Becky Mingyao Ma; Anthony Raymond Tam; Kam Wa Chan; Maggie Kam Man Ma; Ivan Fan Ngai Hung; Desmond Yat Hin Yap; Tak Mao Chan Journal: Front Med (Lausanne) Date: 2022-03-09
Authors: D Tatovic; M A McAteer; J Barry; A Barrientos; K Rodríguez Terradillos; I Perera; E Kochba; Y Levin; M Dul; S A Coulman; J C Birchall; C von Ruhland; A Howell; R Stenson; M Alhadj Ali; S D Luzio; G Dunseath; W Y Cheung; G Holland; K May; J R Ingram; M M U Chowdhury; F S Wong; R Casas; C Dayan; J Ludvigsson Journal: Immunother Adv Date: 2022-01-27
Authors: Jacob Hettenbaugh; Ryan Mullane; Gayle Gillispie; Valerie Shostrom; Linda Flores; Jennifer A Fillaus; Marius C Florescu; Denise Murcek; Ketki K Tendulkar Journal: Infect Dis Rep Date: 2021-12-06